title: Ovarian control of pituitary sensitivity of luteinizing hormone secretion to gonadotropin-releasing hormone in women with the polycystic ovary syndrome.
abstract: This study investigated the ovarian control of LH responsiveness to GnRH in anovulatory women with the polycystic ovary syndrome (PCOS). It is suggested that the enhanced pituitary sensitivity of LH secretion to GnRH in anovulatory women with PCOS is not due to a reduced production but rather to a defect in the interaction of ovarian factors on the hypothalamic-pituitary system.
authors.affiliation: Department of Obstetrics and Gynecology, Medical School, University of Thessalia, Larissa, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Dafopoulos
authors.affiliation: Department of Obstetrics and Gynecology, Medical School, University of Thessalia, Larissa, Greece.
authors.forename: Christos
authors.initials: C
authors.lastname: Venetis
authors.affiliation: Department of Microbiology, Medical School, University of Thessalia, Larissa, Greece.
authors.forename: Spyros
authors.initials: S
authors.lastname: Pournaras
authors.affiliation: Department of Obstetrics and Gynecology, Medical School, University of Thessalia, Larissa, Greece.
authors.forename: Athanasios
authors.initials: A
authors.lastname: Kallitsaris
authors.affiliation: Department of Obstetrics and Gynecology, Medical School, University of Thessalia, Larissa, Greece. Electronic address: messinis@med.uth.gr.
authors.forename: Ioannis E
authors.initials: IE
authors.lastname: Messinis
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000858:Anovulation / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004351:Drug Resistance / Q000187:drug effects / Q000502:physiology; D005260:Female; D005640:Follicle Stimulating Hormone / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D010053:Ovary / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D010902:Pituitary Gland / Q000187:drug effects* / Q000502:physiology; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D011374:Progesterone / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone